Robert Toto, MD, reviews key takeaways from the 2021 Academy of Managed Care Pharmacy meeting regarding healthcare resource utilization for patients with chronic kidney disease (CKD).
October 15th 2021, 3:00pm
A brief overview of the STEP trial and results from intensive blood-pressure control in elderly patients with hypertension.
October 15th 2021, 2:00pm
Insight on the unmet needs in management of heart failure, specifically regarding access to therapeutic agents that can alter the course of disease.
October 8th 2021, 1:30pm
Rajiv Agarwal, MD, MS, reflects on pooled data from the EMPEROR-Reduced and EMPEROR-Preserved trials.
October 8th 2021, 1:00pm
An overview of and results from the EMPEROR-Preserved trial, which tested the effects of empagliflozin in patients with HFpEF.
October 1st 2021, 1:30pm
Considerations for the benefit shown in combining finerenone with SGLT2 inhibitors in patients with type 2 diabetes and CKD.
October 1st 2021, 1:00pm
Rajiv Agarwal, MD, MS, considers the practical implications of the FIDELITY pooled analysis and how it may impact clinical practice.
September 24th 2021, 2:30pm
A review of results from the FIDELITY pooled analysis analyzing finerenone’s impact on cardiorenal morbidity and mortality in patients with type 2 diabetes and CKD.
September 24th 2021, 2:00pm
An overview of the FIDELITY analysis, which pooled data from the FIGARO-DKD and FIDELIO-DKD trials in patients with type 2 diabetes and CKD.
September 23rd 2021, 4:00pm
Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.
September 17th 2021, 1:30pm
Rajiv Agarwal, MD, MS, shares expert insight on the results of FIGARO-DKD with respect to the trial’s primary and secondary end points.
